BG00010

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

RadiculopathySciatica

38 competitors in Radiculopathy

#DrugCompanyPhaseTrials

1

Epidiolex

Jazz Pharmaceuticals

Approved

—2

Trental

VValidus Pharmaceuticals

Approved

13

Advil

KKenvue Brands

Approved

14

Kenalog

BBassett Healthcare

Approved

—5

Marcaine

IInnocoll

Approved

—6

Kenalog

BBausch Health Americas, Inc.

Approved

—7

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—8

Standard Medical Care

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Approved

19

Voltaren

CCerimon Pharmaceuticals

Phase 3

—10

Medrol

Pfizer

Phase 2

1Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sciatica2 trials

Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.

Completed·Biogen·Phase 1·NCT01405833·56 enrolled

Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants

Completed·Biogen·Phase 1·NCT00961766·48 enrolled

Phase 11 trial

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

Completed·Biogen·Phase 1·NCT01842126·54 enrolled

Radiculopathy1 trial

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

Completed·Biogen·Phase 2·NCT01873404·183 enrolled

Details

Drug Info

Related News